Scientists Warn About Potential Misuse of Gene Therapy

Publication
Article
OncologyONCOLOGY Vol 13 No 9
Volume 13
Issue 9

Scientists fear that existing genetic techniques will be misused before the consequences of altering the human blueprint on personal, generational, and societal levels are fully realized. At St. Jude Children’s Research Hospital in Memphis, Tennessee,

Scientists fear that existing genetic techniques will be misused before the consequences of altering the human blueprint on personal, generational, and societal levels are fully realized. At St. Jude Children’s Research Hospital in Memphis, Tennessee, leading ethicists and genetic experts argued that our current ability to manipulate our genes brings with it an obligation to conduct a worldwide discourse, which has not occurred to date.

“Sometimes, as a society, we see what we want to see in technology and fail to look at the down side,” said W. French Anderson, MD, director of Gene Therapy Laboratories at the University of Southern California, School of Medicine. “With something like genetic screening for cancer, the same technology that gives us the ability to eradicate deadly disease carries with it a great potential for misuse.”

Misuse May Lead to Loss of ‘Humanness’

Dr. Anderson also discussed the difference between treatment (using genetic therapy to cure disease) and enhancement (using genetic therapy to create genetically superior humans). He cautioned that genetic engineering may alter our humanness.

Dr. Anderson’s colleague, Eric Juengst, PhD, associate professor of biomedical ethics at Case Western Reserve University School of Medicine and a member of the Committee on Human Genome Diversity of the National Research Council, warned that the problem with enhancement is that it corrupts an individual’s ability to honestly achieve a goal.

“We need to have fair competition in society,” said Dr. Juengst. “Getting top grades, or pole vaulting with pharmaceutical help is cheating—and exclusionary based on cost.”

The country’s leading legal and theological experts and top cancer researchers convened recently to discuss these and other moral, ethical, religious, and scientific questions at the “Ethical Boundaries in Cancer Genetics” symposium hosted by St. Jude.

Recent Videos
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
5 experts are featured in this series
4 experts in this video
Related Content